Success Metrics

Clinical Success Rate

100.0%

Based on 1 completed trials

Completion Rate

100%(1/1)

Active Trials

5(83%)

Results Posted

200%(2 trials)

Phase Distribution

Ph phase_2

33%

Ph phase_1

33%

Ph phase_3

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution6 total trials

Phase 1Safety & dosage

2(33.3%)

Phase 2Efficacy & side effects

2(33.3%)

Phase 3Large-scale testing

2(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(5)

Completed(1)

Detailed Status

Recruiting3

Active, not recruiting2

Completed1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 3

Trials by Phase

Phase 12 (33.3%)

Phase 22 (33.3%)

Phase 32 (33.3%)

Trials by Status

active_not_recruiting233%

recruiting350%

completed117%

Recent Activity

5 active trials

Showing 5 of 6

active_not_recruitingphase_3

Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT05089734

recruitingphase_3

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

NCT05633654

recruitingphase_2

Study of Novel Treatment Combinations in Patients With Lung Cancer

NCT05633667

active_not_recruitingphase_2

Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)

NCT05186974

recruitingphase_1

A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer

NCT06926920

View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials

NCT05089734Phase 3

Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Active Not Recruiting

NCT05633654Phase 3

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

Recruiting

NCT05633667Phase 2

Study of Novel Treatment Combinations in Patients With Lung Cancer

Recruiting

NCT05186974Phase 2

Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)

Active Not Recruiting

NCT06926920Phase 1

A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer

Recruiting

NCT01631552Phase 1

Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer